Ligong LU - Faculty of Health Sciences (FHS)

fhsadmin2023-11-24T11:18:09+08:002019-12-03|

Contact Information

Title

Adjunct Professor

Office

(Office) E12-3032 / (Lab) Zhuhai People’s Hospital No. 79, Road Kang Ning, Zhuhai, China

Phone

(Office) +853 8822 4934 / (Lab) +86 0756-2157401

Email

Ligonglu@um.edu.mo

Teaching

Education
Ph.D.	Cardiovascular Institute of Guangdong Province
M.D.	Sun Yat-sen University

Positions
2016-present	Adjunct Professor, Faculty of Health Sciences, University of Macau
2016-present	Director, Zhuhai People’s Hospital
2016-present	Chief, Zhuhai Interventional Radiology Center
2016-present	Post-doctoral Research Associate, Jinan University
2014-present	Chief, Interventional Radiology Medical Quality Control Center of Guangdong Province
2008-2016	Chief, Interventional Radiology Department, Guangdong Provincial People’s Hospital

Research Interests
Basic and clinical translational research on malignant tumor Peripheral vascular interventional radiology

Representative Publications
Li M, Fu S, Zhu Y, Liu Z, Chen S, Lu L, Liang C. Computed tomography texture analysis to facilitate therapeutic decision making in hepatocellular carcinoma. Oncotarget 2016, 15;7(11):13248-59. Li M, Xin Y, Fu S, Liu Z, Li Y, Hu B, Chen S, Liang C, Lu L. Corona Enhancement and Mosaic Architecture for Prognosis and Selection Between of Liver Resection Versus Transcatheter Arterial Chemoembolization in Single Hepatocellular Carcinomas >5 cm Without Extrahepatic Metastases: An Imaging-Based Retrospective Study. Medicine 2016;95: e2458. Liu B, Huang JW, Li Y, Hu BS, He X, Zhao W, Zheng YB, Lu LG. Arsenic trioxide transarterial chemoembolization with and without additional intravenous administration of arsenic trioxide in unresectable hepatocellular carcinoma with lung metastasis: a single-blind, randomized trial. *J Cancer Res Clin Onco* 2015 Jun;141(6):1103-8. doi: 10.1007/s00432-014-1866-1. Liu B, Huang JW, Li Y, Hu BS, He X, Zhao W, Zheng YB, Lu LG. Single-Agent versus Combination Doxorubicin-Based Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Single-Blind, Randomized, Phase II Trial. *Oncology. 2015;89(1):23-30. doi: 10.1159/000371522. Zhan M, Li Y, Hu B, He X, Huang J, Zhao Y, Fu S, Lu L. Serum microRNA-210 as a predictive biomarker for treatment response and prognosis in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Vasc Interv Radiol.* 2014 Aug;25(8):1279-1287.e1. doi: 10.1016/j.jvir.2014.04.013 Zheng YB, Huang JW, Zhan MX, Zhao W, Liu B, He X, Li Y, Hu BS, Lu LG. Genetic variants in the KDR gene is associated with the prognosis of transarterial chemoembolization treated hepatocellular carcinoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2014;35: 11473-81. Zheng YB, Zhan MX, Zhao W, Liu B, Huang JW, He X, Fu SR, Zhao Y, Li Y, Hu BS, Lu LG. The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib. *Medical* *oncology* 2014;31: 209. Zheng YB, Meng QW, Zhao W, Liu B, Huang JW, He X, Li Y, Hu BS, Lu LG. Prognostic value of serum vascular endothelial growth factor receptor 2 response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. *Medical* *oncology* 2014;31: 843. Fu SR, Zhang YQ, Li Y, Hu BS, He X, Huang JW, Zhan MX, Lu LG, Li JP. Sorafenib continuation after first disease progression could reduce disease flares and provide survival benefits in patients with hepatocellular carcinoma: a pilot retrospective study. *Asian Pacific journal of cancer prevention : APJCP* 2014;15: 3151-6. Wu KT, Wang CC, Lu LG, Zhang WD, Zhang FJ, Shi F, Li CX. Hepatocellular carcinoma: clinical study of long-term survival and choice of treatment modalities. *World* *journal* of *gastroenterology* : WJG 2013;19: 3649-57. Li Y, Zheng YB, Zhao W, Liu B, Hu BS, He X, Huang JW, Lu LG. Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma. *Medical* *oncology* 2013;30: 730. Zheng YB, Zhao W, Liu B, Lu LG, He X, Huang JW, Li Y, Hu BS. The blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib. *Asian Pacific journal of cancer prevention : APJCP* 2013;14: 5527-31. Liang HY, Lu LG, Hu BS, Li Y, Shao PJ. Effects of sorafenib combined with chemoembolization and radiofrequency ablation for large, unresectable hepatocellular carcinomas. *Chinese* *medical* *journal* 2013;126: 4270-6. Chuan-Xing L, Xu H, Bao-Shan H, Yong L, Pei-Jian S, Xian-Yi Y, Xiao-Ning L, Li-Gong L. Efficacy of therapy for hepatocellular carcinoma with portal vein tumor thrombus: chemoembolization and stent combined with iodine-125 seed. *Cancer* *biology* & *therapy* 2011;12: 865-71. Shi M, Lu LG, Fang WQ, Guo RP, Chen MS, Li Y, Luo J, Xu L, Zou RH, Lin XJ, Zhang YQ. Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial. *Journal* of *the* *National* *Cancer* *Institute* 2013;105: 59-68. Kudo M, Han G, Finn RS, Poon RT, Blanc JF, Yan L, Yang J, Lu L, Tak WY, Yu X, Lee JH, Lin SM, et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial. *Hepatology* 2014;60: 1697-707.

Representative Publications

Li M, Fu S, Zhu Y, Liu Z, Chen S, Lu L, Liang C. Computed tomography texture analysis to facilitate therapeutic decision making in hepatocellular carcinoma. Oncotarget 2016, 15;7(11):13248-59.
Li M, Xin Y, Fu S, Liu Z, Li Y, Hu B, Chen S, Liang C, Lu L. Corona Enhancement and Mosaic Architecture for Prognosis and Selection Between of Liver Resection Versus Transcatheter Arterial Chemoembolization in Single Hepatocellular Carcinomas >5 cm Without Extrahepatic Metastases: An Imaging-Based Retrospective Study. Medicine 2016;95: e2458.
Liu B, Huang JW, Li Y, Hu BS, He X, Zhao W, Zheng YB, Lu LG. Arsenic trioxide transarterial chemoembolization with and without additional intravenous administration of arsenic trioxide in unresectable hepatocellular carcinoma with lung metastasis: a single-blind, randomized trial. J Cancer Res Clin Onco 2015 Jun;141(6):1103-8. doi: 10.1007/s00432-014-1866-1.
Liu B, Huang JW, Li Y, Hu BS, He X, Zhao W, Zheng YB, Lu LG. Single-Agent versus Combination Doxorubicin-Based Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Single-Blind, Randomized, Phase II Trial. Oncology. 2015;89(1):23-30. doi: 10.1159/000371522.
Zhan M, Li Y, Hu B, He X, Huang J, Zhao Y, Fu S, Lu L. Serum microRNA-210 as a predictive biomarker for treatment response and prognosis in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Vasc Interv Radiol. 2014 Aug;25(8):1279-1287.e1. doi: 10.1016/j.jvir.2014.04.013
Zheng YB, Huang JW, Zhan MX, Zhao W, Liu B, He X, Li Y, Hu BS, Lu LG. Genetic variants in the KDR gene is associated with the prognosis of transarterial chemoembolization treated hepatocellular carcinoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2014;35: 11473-81.
Zheng YB, Zhan MX, Zhao W, Liu B, Huang JW, He X, Fu SR, Zhao Y, Li Y, Hu BS, Lu LG. The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib. Medical oncology 2014;31: 209.
Zheng YB, Meng QW, Zhao W, Liu B, Huang JW, He X, Li Y, Hu BS, Lu LG. Prognostic value of serum vascular endothelial growth factor receptor 2 response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Medical oncology 2014;31: 843.
Fu SR, Zhang YQ, Li Y, Hu BS, He X, Huang JW, Zhan MX, Lu LG, Li JP. Sorafenib continuation after first disease progression could reduce disease flares and provide survival benefits in patients with hepatocellular carcinoma: a pilot retrospective study. Asian Pacific journal of cancer prevention : APJCP 2014;15: 3151-6.
Wu KT, Wang CC, Lu LG, Zhang WD, Zhang FJ, Shi F, Li CX. Hepatocellular carcinoma: clinical study of long-term survival and choice of treatment modalities. World journal of gastroenterology : WJG 2013;19: 3649-57.
Li Y, Zheng YB, Zhao W, Liu B, Hu BS, He X, Huang JW, Lu LG. Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma. Medical oncology 2013;30: 730.
Zheng YB, Zhao W, Liu B, Lu LG, He X, Huang JW, Li Y, Hu BS. The blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib. Asian Pacific journal of cancer prevention : APJCP 2013;14: 5527-31.
Liang HY, Lu LG, Hu BS, Li Y, Shao PJ. Effects of sorafenib combined with chemoembolization and radiofrequency ablation for large, unresectable hepatocellular carcinomas. Chinese medical journal 2013;126: 4270-6.
Chuan-Xing L, Xu H, Bao-Shan H, Yong L, Pei-Jian S, Xian-Yi Y, Xiao-Ning L, Li-Gong L. Efficacy of therapy for hepatocellular carcinoma with portal vein tumor thrombus: chemoembolization and stent combined with iodine-125 seed. Cancer biology & therapy 2011;12: 865-71.
Shi M, Lu LG, Fang WQ, Guo RP, Chen MS, Li Y, Luo J, Xu L, Zou RH, Lin XJ, Zhang YQ. Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial. Journal of the National Cancer Institute 2013;105: 59-68.
Kudo M, Han G, Finn RS, Poon RT, Blanc JF, Yan L, Yang J, Lu L, Tak WY, Yu X, Lee JH, Lin SM, et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial. Hepatology 2014;60: 1697-707.

Research Grants
The Roles and Epigenetic Mechanisms of Super Enhancer Derived lncRNA-MET in the Promotion of Live Cancer Metastasis via Circulary exosome post Transcatheter Arterial Chemoembolization, 81571785. The Multiple-Disciplinary and Individualized Diagnosis and Treatment of Primary Liver Cancer, 201400000001-3. The Application of High-Throughput Sequencing on the Individualized Treatment of Primary Liver Cancer, 2013B021800180. A Multi-Institutional Randomized Controlled Clinical Study on the Treatment of Primary Liver Cancer with Portal Vein Tumor Thrombosis by the Application of Stenting with 125I Particles, 2011A030400009. The Key Problems of Precise Treatment of Liver Cancer by MRI Guided Radiofrequency Ablation, U1301258.

Research Grants

The Roles and Epigenetic Mechanisms of Super Enhancer Derived lncRNA-MET in the Promotion of Live Cancer Metastasis via Circulary exosome post Transcatheter Arterial Chemoembolization, 81571785.
The Multiple-Disciplinary and Individualized Diagnosis and Treatment of Primary Liver Cancer, 201400000001-3.
The Application of High-Throughput Sequencing on the Individualized Treatment of Primary Liver Cancer, 2013B021800180.
A Multi-Institutional Randomized Controlled Clinical Study on the Treatment of Primary Liver Cancer with Portal Vein Tumor Thrombosis by the Application of Stenting with 125I Particles, 2011A030400009.
The Key Problems of Precise Treatment of Liver Cancer by MRI Guided Radiofrequency Ablation, U1301258.

Professional Activities
Chairman	Cantonese Doctors Association Interventional Doctors Branch
Chairman	Cantonese Medical Association Radiology Medical Branch Intervention Committee
Chairman	Chinese Medical Association Radiology Medical Branch Intervention Group
Vice Chairman	Chinese Doctors Association Interventional Doctors Branch Peripheral Vascular Committee
Vice Chairman	Chinese Anti-Cancer Association Professional Committee of Minimally Invasive Treatment of Cancer
Senior Visiting Scholar	Wayne State University, Detroit Medical Center (DMC)